612 Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma

612 Human ribonucleases act as potential plasma biomarkers for targeted therapy and immunotherapy in hepatocellular carcinoma

Bibliographic Details
Main Authors:	Mien-Chie Hung, Ning Ren, Zhengyu Zha, Chenhao Zhou, Dihua Yu, Chunxiao Liu
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2021-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Targeting ALK averts ribonuclease 1-induced immunosuppression and enhances antitumor immunity in hepatocellular carcinoma
by: Chunxiao Liu, et al.
Published: (2024-02-01)

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases
by: Ying-Nai Wang, et al.
Published: (2018-11-01)

MiR-612 regulates invadopodia of hepatocellular carcinoma by HADHA-mediated lipid reprogramming
by: Yang Liu, et al.
Published: (2020-02-01)

SITE-612
by: Poag, C, et al.
Published: (1987)

Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment
by: Zhou Jiang, et al.
Published: (2020-07-01)

Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma
by: Xuenan Peng, et al.
Published: (2023-01-01)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
by: Yuqing He, et al.
Published: (2021-09-01)

Prognostic stratification based on m5C regulators acts as a novel biomarker for immunotherapy in hepatocellular carcinoma
by: Ping Liu, et al.
Published: (2022-09-01)

Liquid biopsy to identify biomarkers for immunotherapy in hepatocellular carcinoma
by: Huang Ao, et al.
Published: (2021-12-01)

Carrot ribonucleases
by: T. Gołaszewski, et al.
Published: (2015-01-01)

miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway
by: Xing K, et al.
Published: (2023-12-01)

Application of Immunotherapy in Hepatocellular Carcinoma
by: Lele Miao, et al.
Published: (2021-08-01)

Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma
by: Tiantian Liu, et al.
Published: (2022-10-01)

Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas
by: Zhanjun Guo, et al.
Published: (2022-03-01)

Current Landscape and Future Directions of Biomarkers for Immunotherapy in Hepatocellular Carcinoma
by: Gok Yavuz B, et al.
Published: (2021-09-01)

Semisynthesis of Human Ribonuclease–S
by: Sayers, Jessica, et al.
Published: (2022)

Semisynthesis of Human Ribonuclease–S
by: Sayers, Jessica, et al.
Published: (2022)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
by: Qiang Zhou, et al.
Published: (2023-06-01)

Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma.
by: Rucksak Rucksaken, et al.
Published: (2014-01-01)

MiR-612, miR-637, and miR-874 can Regulate VEGFA Expression in Hepatocellular Carcinoma Cell Lines
by: Márcia Maria U. Castanhole-Nunes, et al.
Published: (2022-01-01)

Ribonucleases as potential therapeutic agents
by: Masoume Vakili-Azghandi, et al.
Published: (2021-03-01)

Secreted alkaline ribonucleases of micromycetes
by: V.V. Ulyanova, et al.
Published: (2020-09-01)

Ribonuclease-Responsive DNA Nanoswitches
by: Arun Richard Chandrasekaran, et al.
Published: (2020-07-01)

AGW 612 - CORPORATE STRATEGY APRIL 08.
by: PPP, Pusat Pengajian Pengurusan
Published: (2008)

AGW 612 — Corporate Strategy - February 2000
by: PPP, Pusat Pengajian Pengurusan
Published: (2000)

HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
by: Guoming Chen, et al.
Published: (2023-02-01)

GTPBP4 promotes hepatocellular carcinoma progression and metastasis via the PKM2 dependent glucose metabolism
by: Qiang Zhou, et al.
Published: (2022-10-01)

Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation
by: Heng-Huan Lee, et al.
Published: (2021-05-01)

Advances in Immunotherapy for Hepatocellular Carcinoma
by: Satoru Hagiwara, et al.
Published: (2023-03-01)

Immunotherapies for advanced hepatocellular carcinoma
by: Li-Yang Sun, et al.
Published: (2023-03-01)

Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
by: Marron TU, et al.
Published: (2022-06-01)

Editorial: Immunotherapy in Hepatocellular Carcinoma
by: Bin Li, et al.
Published: (2021-06-01)

Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals
by: Loraine Kay D. Cabral, et al.
Published: (2022-05-01)

HULC and Linc00152 Act as Novel Biomarkers in Predicting Diagnosis of Hepatocellular Carcinoma
by: Jun Li, et al.
Published: (2015-09-01)

A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy
by: Sooyeon Oh, et al.
Published: (2020-03-01)

Identification of VRK1 as a Novel Potential Biomarker for Prognosis and Immunotherapy in Hepatocellular Carcinoma
by: He X, et al.
Published: (2024-03-01)

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
by: Maria Pallozzi, et al.
Published: (2022-09-01)

CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
by: Lin Chen, et al.
Published: (2021-10-01)

Phenotype of ribonuclease 1 deficiency in mice
by: Garnett, Emily Rose, et al.
Published: (2020)

Circular zymogens of human ribonuclease 1
by: Windsor, Ian W., et al.
Published: (2022)